Start: January 8, 2021
End: September 2025
This pilot study will evaluate the safety and feasibility of [11C]MPC6827 as an imaging tracer to detect the early breakdown of neurons, called neurodegeneration, in people with Alzheimer's disease or amyotrophic lateral sclerosis (ALS). In the first part of the study, up to five healthy volunteers will be injected with a small dose of the tracer followed by positron emission tomography (PET) and computed tomography (CT) full-body imaging scans. Next, up to 30 participants, including healthy volunteers and adults with Alzheimer's and ALS, will be injected with a full dose of the tracer followed by extended imaging with up to two hours of PET-CT scans to assess the body's processing of the tracer over time. Researchers will monitor all participants for safety and any adverse events throughout the study.
Minimum Age: 18 Years
Maximum Age: N/A
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Cuimc / Nyp
New York, NY 10032
RecruitingRodolfo Arevalo, BA
Lead: Columbia University
Source: ClinicalTrials.gov ID: NCT04575727